FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer

The FDA granted accelerated approval to GSK's dostarlimab (Jemperli) for treating stage II/III dMMR rectal cancer. In the AZUR-1 trial, 47% of patients achieved a 12-month clinical complete response. The approval introduces a nonoperative management pathway, avoiding chemotherapy, radiation, and surgery for responding patients. The FDA reviewed additional supporting data and approved the application ahead of schedule.

Original reporting
Published Oct 19, 2026, 4:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 6:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer — source image
Decision brief

The 30-second read

$GSKBullishHigh
01

Why it matters

The approval could add several hundred million dollars to GSK's revenue forecasts if the indication gains market share.

02

Market read

First‑report FDA approval for a major oncology drug, likely to move GSK stock and influence the biotech sector.

03

What to watch

Potential reimbursement challenges and the need for confirmatory Phase 3 data could temper the rally.

Relevance 7/10Novelty 9/10Timing: today

Background

The FDA's Project Orbis and Real‑Time Oncology Review expedited the review, reflecting regulatory momentum for breakthrough immunotherapies.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

FDA granted accelerated approval to GSK's dostarlimab for dMMR/MSI-H locally advanced rectal cancer.

Expected impact

likely upward pressure as investors price in the new indication and potential sales uplift.

Evidence & confidence

Regulatory approval is a primary catalyst; GSK is a large‑cap biotech with significant market exposure, and the data show strong response rates.

Market effects

Strengthens the dMMR/MSI-H oncology segment and may lift peers with similar immunotherapy pipelines.

Positive for European biotech stocks, especially UK‑listed pharma companies.

Adds to the broader trend of accelerated approvals for immuno‑oncology drugs worldwide.

Counterpoint

Skeptics may argue the single‑arm trial lacks a comparator and long‑term data, limiting commercial upside.

Key entities

  • GlaxoSmithKline

    Pharmaceutical company developing dostarlimab (Jemperli).

  • FDA

    U.S. Food and Drug Administration granting accelerated approval.

Related articles

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.